Home › Compound Library › Enoxaparin (Lovenox)

Enoxaparin (Lovenox)

Anticoagulantprescriptionsubcutaneous · inferred

Low molecular weight heparin (LMWH, ~4500 Da) derived from unfractionated heparin by alkaline benzylation and depolymerization. Binds to and potentiates antithrombin III via a unique pentasaccharide sequence, primarily accelerating factor Xa inactivation (anti-Xa:anti-IIa ratio ~4:1 vs 1:1 for UFH). Predictable linear pharmacokinetics with SC bioavailability ~90-100%, obviating routine coagulation monitoring required for UFH. Renally cleared; dose adjustment needed in CKD (CrCl <30 mL/min). Lower risk of HIT (~0.5% vs ~3% for UFH) and osteoporosis. Approved for DVT prophylaxis/treatment, PE, unstable angina/NSTEMI, and STEMI.

Projected serum levels — 40 mg, twice daily

Enoxaparin (Lovenox)
Enoxaparin (Lovenox) modeled serum levels, 40 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 12.5 25 37.5 50 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Enoxaparin (Lovenox) modeled serum levels with a loading dose of 53.2 mg, then 40 mg twice daily The first dose is larger so levels approach steady state faster. 0 12.5 25 37.5 50 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 40 mg twice daily (subcutaneous).

Loading schedule: 53.2 mg on day 1, then 40 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 28.6 mg, trough ≈ 11.9 mg body load. Population-based estimate over 15 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Anticoagulant
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
4.5 h
Common dose
40 mg
Suggested maximum
100 mg/day
Reference dose range
20–100 mg (single dose)
Suggested cadence
twice daily

Research behind this entry

  1. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease Cohen M et al. (ESSENCE Investigators) · New England Journal of Medicine, 1997 DOI

    Landmark ESSENCE trial (n=3,171) demonstrating enoxaparin superiority over UFH in unstable angina/NSTEMI — 16% relative risk reduction in the composite of death, MI, or recurrent angina at 14 days. Established LMWH as…

  2. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial Antman EM et al. (TIMI 11B Investigators) · Circulation, 1999 DOI

    TIMI 11B trial (n=3,910) confirming ESSENCE findings — enoxaparin reduced death, MI, or urgent revascularization vs UFH (12.4% vs 14.5%, p=0.048) in UA/NSTEMI patients. Prolonged outpatient enoxaparin provided no…

  3. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction Antman EM et al. (ExTRACT-TIMI 25 Investigators) · New England Journal of Medicine, 2006 DOI

    ExTRACT-TIMI 25 (n=20,506) — enoxaparin vs UFH as adjunct to fibrinolysis in STEMI. Enoxaparin reduced death or recurrent MI at 30 days (9.9% vs 12.0%, p<0.001) at the cost of increased major bleeding (2.1% vs 1.4%).…

3 published studies referenced in the app, each with a plain-language summary.